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Abstract 
There are direct relationships between work in process 
inventory, cycle time, and throughput for most 
manufacturing processes.  Companies that focus on 
lean manufacturing principles are aware of these 
relationships, and strive to minimize work in process 
and cycle times in order to maximize their 
manufacturing efficiencies.  A study has been 
conducted to determine whether some of these 
relationships can be seen at the corporate level.  Many 
companies have recently begun reporting more detailed 
information regarding their inventory figures, and 
include work in process data in their annual reports.  
Several industries are investigated here to determine 
whether corporate results reflect their concern – or lack 
of concern - regarding manufacturing efficiencies.  Of 
particular interest are the automotive, the consumer 
goods, and the pharmaceutical industries. 
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Introduction 
Lean manufacturing concepts have been widely 
publicized since the 1980’s, and many industries have 
embraced these concepts.  Toyota Motor Corporation is 
generally credited with creating the concept of lean 
manufacturing.  The “Toyota Production System” 
evolved out of need; during the 1970’s the company 
simply did not have the resources to spend on excess 
inventory.  The system was developed to eliminate 
waste wherever it was found, including scrap, 
inventories, and off-quality material.  Over time, 
Toyota began eliminating wasted time as well as 
wasted materials (Ohno, 1988). 
The objective of lean manufacturing is to 
streamline the flow of materials though the production 
process (Standard & Davis, 1999).  While many of the 
techniques have been applied across the automobile 
industry, not all industries have embraced the ideas of 
lean manufacturing.  Experience has shown that many 
of the concepts have been applied in the consumer 
goods industry, but these ideas are not understood in 
the pharmaceutical industry.  This observation has also 
been documented in the literature (Elliott, 2006). 
Factory Physics® is a description of the underlying 
behavior of manufacturing systems; a ‘science’ of 
manufacturing (Hopp & Spearman, 2001).  The tools 
of Factory Physics allow a person to identify areas of 
improvement in serial production lines.  This can be 
applied to not only metal fabrication, but also to the 
chemical process industries.   Internal benchmarking 
can be used to identify how well a manufacturing 
operation is functioning compared to its own ideal 
potential.  Internal benchmarking can also be used as a 
tracking tool to gauge improvements made to an 
operation. 
These tools have been successfully applied to 
individual operations in a wide assortment of 
companies and industries.  The tools are meant to be 
applied to individual production lines, to measure and 
improve the efficiency of manufacturing systems.  The 
tools are used at a micro level. 
Can these tools be applied to the corporation as a 
whole?  Do the micro-level tools also work at a macro 
level?  Can a company’s average efficiency be 
determined and compared to others?  This paper is a 
work in process to determine whether some of the lean 
manufacturing relationships can be seen at the 
corporate level, using publicly available financial 
accounting data. 
 
Manufacturing Efficiency 
Various industries have taken different approaches to 
the subject of manufacturing efficiency.  Some, such as 
the automobile industry, have a high cost of goods 
relative to their income.  Some, such as 
pharmaceuticals, have a relatively low cost of goods.  
Manufacturing is a key cost center for automobiles, but 
is not a focus for pharmaceuticals.  Manufacturing 
efficiency is very important to the profitability of the 
auto industry, but is almost a foreign concept to the 
prescription drug business. 
Ohno (1988) described seven types of waste, 
saying that true efficiency improvement comes when 
we produce no waste and bring the percentage of work 
to 100 percent.  The seven types of waste were 
identified as: 
1.  Overproduction 
2.  Waiting; waste of time on hand 
3.  Transportation; moving materials around the 
plant 
4.  Over processing; effort to deliver features that 
have no value 
5.  Inventory 
6.  Motion; movement of people, tooling, and 
equipment that does not add value 
 1
7.  Defective product. 
Sometimes an 8th item is added to the list (Alukal, 
2003): 
8.  People; not fully using a person’s mental and 
creative skills and experiences. 
Eliminating these wastes can significantly improve 
operating efficiency.  
 In recent years, industry has significantly reduced 
manufacturing costs by a variety of methods.  One of 
the primary methods has been the reduction of 
inventory, resulting in a decrease in the amount of 
capital that is tied up in the manufacturing process 
(Riggs, 2004). 
 
Work in Process, Inventory, and Cycle Time.  
Studies of serial production systems have been around 
since the industrial revolution, including Adam Smith’s 
famous description of the pin factory (1789).  In the 
1980s, various mathematical modeling studies were 
conducted studying work in process inventory 
(Conway, 1988).   
In an effort to better explain the nature of serial 
production lines, John D.C. Little (1992) proposed 
“Little’s Law”, which was based on queuing theory: 
 
L = λW (1) 
 
where   
L =  the average number of items present  
  in the system 
λ =  the average arrival rate, items per            
  unit of time 
W = the average time spent by an item            
 in the system. 
 
This relationship proved to be valid under a wide range 
of conditions.  The notation of Little’s Law was 
changed by Hopp and Spearman (2001) and used as a 
basis for Factory Physics: 
 
WIP = TH x CT (2) 
 
where 
WIP = Work in process inventory 
TH   = Throughput of the process, items per        
      unit of time 
CT   = Average cycle time, from the start        
      of the process to its end. 
 
The minimum level of WIP can be determined 
using the fastest possible throughput (the bottleneck 
rate) and the fastest possible cycle time.  The 
bottleneck rate, rb, is the rate of the workstation that 
limits the throughput of the process.  The raw process 
time, T0, is the sum of the individual unit operation 
times; it does not include time that materials spend 
waiting to be processed.  The Critical WIP, W0, is the 
inventory of a perfect process, operating at the 
bottleneck rate and the raw process time.  This is a 
theoretically perfect process (Hopp & Spearman, 
2001): 
 
W0 = rbT0   (3) 
 
Any time delays, such as waiting to begin the next 
step in the process, will increase the cycle time to 
beyond T0, and will increase WIP to beyond W0.   
Companies that operate with short cycle times, such as 
many consumer product companies, will experience 
relatively small levels of WIP.  Companies that operate 
with long cycle times, such as prescription drugs, will 
operate with much larger levels of WIP.  Often, the 
differences in cycle times are driven not by the nature 
of the process, but rather by how companies choose to 
manage their operations. 
 
Internal Benchmarking.  Factory Physics’ Best-Case 
Performance Law (Hopp & Spearman, 2001) identifies 
the minimum cycle time and the maximum throughput 
for a given WIP level (w) as: 
  
 best 0 0
b
CT     =  T        if 
w            =     otherwiser
w W≤
 (4) 
  
  best 00
b
TH       if 
           =  r          otherwise
w w WT= ≤  (5) 
  
The worst case performance for a given inventory 
level (w) is defined by: 
 
 worst 0CT   wT=  (6) 
 
worst
0
1TH   T=  (7) 
 
This represents the highest cycle time and the smallest 
throughput for a process having a raw process time of 
T0.   
No process will operate at either the best case or 
the worst case levels, but rather will usually operate 
somewhere between.  It is helpful to have an idea of 
what might be considered “good”.  The following 
represents what the authors call the practical worst case 
or the marginal case (Absolute Benchmarking, 2004). 
 
 
PWC 0
1CT  = 
b
wT
r
−+  (8) 
 
PWC
0
TH  = 
1 b
w r
W w+ −
 (9) 
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The marginal case determines the division that 
distinguishes good performance from bad, or lean 
performance from poor.  Best case, worst case, and 
marginal case performance can be shown graphically.  
The relationship between work in process and cycle 
time is shown in Exhibit 1.  The space between the 
marginal line and the best case line is the good region, 
and can be considered the area of lean manufacturing.  
The space between the worst case line and the practical 
worst case line is considered the bad region, and is not 
where a factory wants to be operating.   
 
Exhibit 1.  Cycle Time and Work in Process. 
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The relationship of work in process and throughput is 
shown in Exhibit 2.  The area above the practical worst 
case curve is considered good, or the lean region.  
Operation below the marginal case line is considered 
inefficient. 
 
Exhibit 2.  Throughput and Work in Process. 
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Nearly any sequential process can be mapped 
using these graphical tools.  The math is applicable to 
an assembly operation or a chemical process.   
Companies that focus on lean manufacturing principles 
are aware of these relationships, and strive to minimize 
work in process and cycle times in order to maximize 
their manufacturing efficiencies. 
These tools and relationships are used for 
individual process, assembly, and packaging 
operations.  While the tools are widely applicable, the 
individual variables are specific to a given operation.  
They are meant to be used on a micro scale.   
 
Method 
Financial Information.  In the past few years, 
companies have been reporting more detailed 
information in their annual financial statements.  
Overall inventories have historically been given, but 
many companies are now reporting results that include 
raw materials, work in process, and finished product 
inventories.  This added information provides 
additional insight into a firm’s operations.  The fact 
that this new information is available to the public 
spawned a question.  If lean manufacturing tools like 
internal benchmarking can be used to gauge the 
efficiency of an individual operation, can the same 
tools be used to gauge the efficiency of a company as a 
whole?  Annual financial information considers the 
firm as a whole.  The reported data is a composite of 
the entire company, and only grand averages can be 
considered.  Also, it must be remembered that the 
reported inventories represent a snapshot in time.  
Nevertheless, it was felt that if a firm widely practiced 
lean manufacturing principles, the results should show 
as an improvement relative to firms that did not 
practice lean manufacturing.   
Annual financial information was gathered from 
publicly available data.  Sources included annual 
reports available on the internet, public listings and 
reports from brokerage firms, and internet search 
engines.  The following industries were investigated: 
 
Automobile industry 
Consumer household products 
U.S. Pharmaceutical industry 
   Prescription drug firms (“Big Pharma”) 
   Generic drug firms  
 
Information was collected for fiscal years ending 
in 2003, 2004, and 2005 where available.  The 
following information was gathered: 
 
Sales (Revenue) 
Cost of goods sold (COGS) 
Total inventory 
Raw materials 
Work in Process (WIP) 
Finished goods 
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The above data was assembled and standard financial 
ratios were determined.  Graphs similar to the internal 
benchmarking graphs shown in Exhibits 1 and 2 were 
also made. 
 
Cycle Time.  An important variable for any 
manufacturing process is the system’s cycle time.  The 
amount of time to process a raw material into a 
finished product ready for shipping has a profound 
impact on the operation’s WIP.  Consider how long it 
takes Procter & Gamble to make a bottle of liquid 
detergent from its individual components.  Chemicals 
can be mixed and packaged and put in the warehouse 
in a mater of a few hours.  Very little time or WIP is 
involved.  When P&G started NyQuil Liquicaps, the 
process cycle time to make unpackaged bulk capsules 
was six weeks.  The resulting work in process was 
much greater than the company was used to dealing 
with.   
How does one translate an individual cycle time to 
a corporate average?  Most companies have a wide 
range of products, each having its own unique process 
and cycle time average.  While a relationship may yet 
be found, this has not been explored.  From an initial 
perspective, cycle time cannot be expanded to a 
corporate average and still make sense. 
 
Throughput.  The throughput of a process is the 
amount of product made per unit of time.  This can be 
tons per hour, cases per day, or any unit of measure 
that the firm wants to use.  In terms of corporate 
averages, the throughput of the firm is its sales, or 
revenue.  However, the firm’s sales are in terms of 
sales dollars, not cost dollars; sales figures include 
profit.  If we want to compare inventory and 
throughput on a common basis, then cost of goods sold 
is a better measure of throughput.  That is why the 
financial ratio for inventory turnover uses cost of goods 
sold, not sales (Penman, 2004). 
 
Inventory.  Total inventory is widely reported in 
annual financial reports.  In the past few years, many 
companies (but certainly not all) have begun reporting 
raw material, work in process, and finished product 
inventories separately.  Some firms, notably those in 
the automotive industry, report raw material and work 
in process combined.   
Sufficient information exists to do comparisons of 
various firms.  The relationship between the cost of 
goods sold and work in process inventory can be 
investigated.  What cannot be done is determine a 
precise region for lean manufacturing.  The equations 
used for determining the lean region apply to specific 
processes.  These cannot be averaged to apply to a 
corporate result.   
A company that has a high throughput will tend to 
have a high work in process inventory.  However, a 
lower WIP for a given level of throughput will identify 
a company as being more efficient.  So while the 
relationship between throughput and work in process is 
valid, the resulting graph cannot be used to determine 
whether a company qualifies as being “lean”.  
Companies can be compared to each other, however. 
 
Results 
Automobiles.  Lean manufacturing began in the 
automobile industry and has been widely embraced.  
Just in Time (kanban) systems are in use throughout 
the business.  The companies investigated include 
Daimler Chrysler, Toyota, Honda, Nissan, and 
Volkswagen.  General Motors and Ford do not report 
WIP inventories.   
Data from these companies is shown in Exhibit 3 
and plotted in Exhibit 4.  If the data represented total 
inventory instead of work in process inventory, the 
widely used financial ratio Inventory Turnover could 
be used, which is defined as (Fraser & Ormiston, 
2007): 
 
 Inventory Turnover = COGS / Inventory  (10) 
 (in turns per year) 
  
The data suggests a similar pattern, so a lesser known 
ratio is used, WIP Turnover, defined as:  
 
 WIP Turnover = COGS / WIP Inventory (11) 
 (in turns per year) 
 
Exhibit 3.  Financial data for the Automotive Industry. 
 
(In millions of dollars)
Company Year COGS WIP WIP Turnover
Toyota 2003 99,120 1,110 89.3
2004 127,792 1,567 81.6
2005 135,025 1,676 80.6
Daimler Chrysler 2003 109,926 2,280 48.2
2004 114,567 2,545 45.0
Honda 2330 45,010 197 228.5
2004 53,078 210 252.8
2005 56,227 233 241.3
Nissan 2003 50,096 1,471 34.1
2004 59,358 1,926 30.8
Volkswagen 2003 74,099 1,308 56.7
2004 82,391 1,289 63.9
2005 78,430 1,355 57.9  
 
Since WIP should be minimized, a high WIP Turnover 
number is preferable.  Companies that have a higher 
WIP Turnover can be seen as having less WIP relative 
to their throughput, and are operating under more lean 
conditions.  An example is Toyota, which has the two 
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highest values for Cost of Goods sold in Exhibit 4.  
Toyota has an average WIP Turnover ratio of 84 during 
the 2003 - 2005 period.  Honda, which has the smallest 
WIP, also has the highest WIP Turnover ratio at 241.  
Nissan has the lowest ratio at 32. 
 
Exhibit 4.  COGS and WIP for the Automotive 
Industry. 
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 There appears to be a linear relationship among 
these companies.  A regression line was determined, 
but the results were fairly weak, with r = 0.63 and r2 = 
0.40.  Additional data will be needed to determine if a 
correlation exists between these variables within the 
industry. 
 
Consumer Products.  Another industry that started 
adopting lean manufacturing practices many years ago 
is household consumer products.  Corporate 
information is shown in Exhibit 5 and plotted in 
Exhibit 6.  A strong linear correlation exists; the 
regression line is shown, with r = 0.99 and r2 = 0.98.  
Procter & Gamble, the largest of the companies shown, 
has an average WIP Turnover of 76, roughly in line 
with the best of the automobile companies.  Although 
the cost of goods for individual items is far less in this 
industry than in automobiles, the sheer volume makes 
this a category where inventories must be closely 
managed.  The consumer products industry appears to 
be doing well, if automobiles are a benchmark. 
 
Prescription Drugs.  The pharmaceutical business is 
known to focus on research and the quest for new drug 
products.  Manufacturing is not a focus area for the big 
pharmaceutical companies (Woodcock, 2001).  Exhibit 
8 displays data from Pfizer, Johnson & Johnson, 
Bristol Myers Squibb, Lilly, Abbott, and Schering-
Plough.  Unlike the consumer products companies, we 
see a wide diversity of results.  In Exhibit 8, the most 
‘lean’ companies will have results toward the upper left 
corner.  Abbott, Johnson & Johnson, and Bristol Myers 
Squibb appear to have the best results.  It should be 
noted that among this group, Johnson & Johnson is 
probably the least typical pharmaceutical company; 
they have substantial over the counter and medical 
devise businesses.  Pfizer is the largest traditional 
prescription drug company, and has some of the 
poorest results of the group with an average WIP 
turnover of 3.5, compared to Abbott’s average of 15.4.  
Clearly, this industry is operating with far higher work 
in process inventories than the automobile or consumer 
products industries.  In part, this is due to the highly 
regulated nature of the industry. 
 
Exhibit 5.  Financial Data for the Household Products 
Industry. 
 
(In millions of dollars)
Company Year COGS WIP WIP Turnover
Procter & Gamble 2003 22,141 291 76.1
2004 25,076 340 73.8
2005 27,804 350 79.4
Colgate 2003 4,456 30.4 146.6
2004 4,747 37.3 127.3
2005 5,192 37.5 138.5
Pepsico 2003 12,379 160 77.4
2004 13,406 156 85.9
2005 14,176 112 126.6
Clorox 2003 2,171 9 241.2
2004 2,331 3 777.0
2005 2,493 6 415.5
Estee Lauder 2003 1,324 34 38.9
2004 1,476 37 39.9
Revlon 2003 501 12 41.8
2004 485 12 40.4
2005 508 18 28.2  
 
 
Exhibit 6.  COGS and WIP for the household products 
industry. 
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Exhibit 7.  Financial Data for the Pharmaceutical 
Industry. 
 
(In millions of dollars)
Company Year COGS WIP WIP Turnover
Johnson and Johnson 2003 12,176 981 12.4
2004 13,422 1113 12.1
2005 13,954 1073 13.0
Pfizer 2003 9,589 2,198 4.4
2004 7,541 2,850 2.6
2005 8,525 2,379 3.6
Bristol Myers Squibb 2003 5,406 416 13.0
2004 5,989 458 13.1
2005 5,928 679 8.7
Lilly 2003 2,675 1,169 2.3
2004 3,224 1,356 2.4
2005 3,474 1,272 2.7
Abbott 2003 7,774 546 14.2
2004 8,884 583 15.2
2005 10,641 630 16.9
Schering Plough 2003 2,833 648 4.4
2004 3,070 651 4.7
2005 3,346 614 5.4  
 
Exhibit 8.  COGS and WIP for the Pharmaceutical 
Industry. 
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Generic Drugs.  The generic drug industry represents 
a different part of the pharmaceutical business.  
Generic companies have much of their business in the 
field of prescription drugs that have gone off-patent.  
The research focus is much less, the competition is 
more intense, and the impact of manufacturing cost is 
much greater in the generic companies.  The regulatory 
nature and the manufacturing processes are quite 
similar to “Big Pharma”.  A key difference is that the 
large companies are focused on research while the 
generic companies are focused on manufacturing. 
 Exhibit 9 shows the financial data for 2003 – 
2005.  The linear relationship seen in Exhibit 10 is 
again present, with an r of 0.94 and r2 of 0.88, implying 
a common relationship between COGS and WIP 
among the companies shown.  TEVA is the largest of 
the companies shown, with an average WIP turnover of 
15.1, equivalent to the best of the ‘Big Pharma’ 
companies.  The highest average WIP turnover value 
was Barr Laboratories with 26.2.  The WIP turnover 
results for the generic companies are higher than the 
Big Pharma companies, implying a heightened concern 
for manufacturing and a more “Lean” manufacturing 
style. 
 
Exhibit 9.  Financial Data for the Generic Drug 
Industry. 
 
(In millions of dollars)
Company Year COGS WIP WIP Turnover
Watson 2003 625 70.4 8.9
2004 821 70.2 11.7
2005 852 67.2 12.7
Teva 2003 1,758 150 11.7
2004 2,560 169 15.1
2005 2,770 149 18.6
Mylan 2003 598 34 17.6
2004 612 35 17.5
2005 630 40 15.8
Barr Laboratories 2003 424 19 22.3
2004 633 17 37.2
2005 304 16 19.0
Elan 2003 250 21.3 11.7
2004 174 8.2 21.2
2005 192 9.7 19.8
Perrigo 2003 596 59 10.1
2004 630 59 10.7
2005 764 59 12.9  
 
Exhibit 10.  COGS and WIP for the Generic Drug 
Industry. 
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Conclusions & Recommendations 
This initial work has identified that there are definite 
relationships between work in process inventory and 
the cost of goods sold within specific industries.  The 
relationship can be seen at the corporate level within 
the finances of the firm.  Industries that tend to 
embrace lean manufacturing concepts, such as the 
automotive industry and the household consumer 
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products companies tend to have a high WIP turnover.  
The Pharmaceutical industry, where manufacturing 
efficiencies are not a focus, have very low WIP 
turnovers.  Generic drug companies, which comprise a 
subset of the pharmaceutical industry, have 
significantly higher WIP turnovers than the big 
pharmaceutical firms.  The focus – or lack of focus – 
on manufacturing efficiency is reflected in the firm’s 
annual accounting statements. 
Further work includes expanding the current 
database and looking at additional industries.  One 
industry of particular interest is consumer electronics, 
where Dell built a business model on fast cycle times 
and low inventories of custom built computers. 
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